Iradimed (IRMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.46
- EPS estimate
- $0.44
- EPS surprise
- +4.55%
- Revenue surprise
- +0.57%
- Revenue
- $20.5M
- Revenue estimate
- $20.4M
- Reported
- Jul 31, 2026
Iradimed reported Q2 2026 results on July 31, 2026. Earnings per share were $0.46, ahead of the $0.44 estimate by 4.55%. Revenue was $20.5 million, just above the $20.4 million consensus. Compared with Q2 2025, EPS fell about 6% from $0.49, while revenue edged up from $20.4 million. The first half of 2026 still adds up to $0.95 per share, about 4% more than the $0.91 of the same period a year earlier.
The longer record shows steady growth. Annual EPS rose from $1.09 in 2022 to $1.48 in 2023, $1.65 in 2024 and $1.92 in 2025, up about 76%. Annual revenue grew from $53.3 million to $83.8 million over the same span. Q4 2025 set the highs in the table at $0.54 per share and $22.7 million in revenue. Iradimed has reported a profit in every quarter shown. Over the last 20 quarters, it beat the EPS estimate 19 times and matched it once, in Q4 2024.
Iradimed reported Q3 results between October 29 and November 3 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether EPS returns to growth.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 31, 2026 | $0.44 | $0.46 | +4.55% | $20.5M | SEC |
| Q1 2026 | May 1, 2026 | $0.45 | $0.49 | +10.11% | $22.0M | SEC |
| Q4 2025 | Feb 10, 2026 | $0.48 | $0.54 | +12.50% | $22.7M | SEC |
| Q3 2025 | Nov 3, 2025 | $0.46 | $0.47 | +3.30% | $21.2M | SEC |
| Q2 2025 | Aug 1, 2025 | $0.44 | $0.49 | +12.64% | $20.4M | SEC |
| Q1 2025 | May 5, 2025 | $0.41 | $0.42 | +2.44% | $19.5M | SEC |
| Q4 2024 | Feb 13, 2025 | $0.44 | $0.44 | +0.00% | $19.4M | SEC |
| Q3 2024 | Oct 31, 2024 | $0.41 | $0.43 | +6.17% | $18.3M | SEC |
| Q2 2024 | Aug 1, 2024 | $0.37 | $0.42 | +15.07% | $17.9M | SEC |
| Q1 2024 | May 2, 2024 | $0.34 | $0.36 | +7.46% | $17.6M | SEC |
| Q4 2023 | Feb 8, 2024 | $0.38 | $0.39 | +2.63% | $17.5M | SEC |
| Q3 2023 | Nov 3, 2023 | $0.36 | $0.43 | +18.36% | $16.5M | SEC |
| Q2 2023 | Aug 3, 2023 | $0.31 | $0.36 | +16.13% | $16.1M | SEC |
| Q1 2023 | May 4, 2023 | $0.28 | $0.30 | +5.89% | $15.5M | SEC |
| Q4 2022 | Feb 2, 2023 | $0.30 | $0.32 | +6.67% | $14.9M | SEC |
| Q3 2022 | Nov 3, 2022 | $0.25 | $0.29 | +18.37% | $13.4M | — |
| Q2 2022 | Jul 29, 2022 | $0.24 | $0.26 | +10.64% | $12.7M | — |
| Q1 2022 | Apr 29, 2022 | $0.21 | $0.22 | +4.76% | $12.3M | — |
| Q4 2021 | Feb 4, 2022 | $0.20 | $0.33 | +69.23% | $11.9M | — |
| Q3 2021 | Oct 29, 2021 | $0.17 | $0.23 | +35.29% | $10.9M | — |
Quarterly revenue
Frequently asked questions
When did Iradimed (IRMD) last report earnings?
Iradimed last reported on Jul 31, 2026, covering fiscal Q2 2026.
Did IRMD beat earnings estimates?
Yes. Iradimed reported EPS of $0.46 for Q2 2026 against a $0.44 estimate — a 4.55% beat.
How much revenue did IRMD report last quarter?
Iradimed reported $20.5M in revenue for Q2 2026, against a consensus estimate of $20.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.